STOCK TITAN

Denali Therapeutics Inc - DNLI STOCK NEWS

Welcome to our dedicated news page for Denali Therapeutics (Ticker: DNLI), a resource for investors and traders seeking the latest updates and insights on Denali Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Denali Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Denali Therapeutics's position in the market.

-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
Denali Therapeutics Inc

Nasdaq:DNLI

DNLI Rankings

DNLI Stock Data

2.54B
120.16M
13.79%
79.49%
6.77%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
South San Francisco

About DNLI

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).